Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
Name
Wittrup_Effect of small.pdf
Size
991.51 KB
Format
Adobe PDF
Checksum (MD5)
826ca01c076f57b62c3ee9f75977d5fe
Author(s)
Rhoden, John J.
Ruiz-Yi, Benjamin
Wittrup, Karl Dane
Frangioni, John V.
Orcutt, Kelly Davis
Date Issued
April 2012
Journal
Molecular Cancer Therapeutics
Publisher
American Association for Cancer Research
Citation
Orcutt, K. D., J. J. Rhoden, B. Ruiz-Yi, J. V. Frangioni, and K. D. Wittrup. “Effect of Small-Molecule-Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody.” Molecular Cancer Therapeutics 11, no. 6 (April 5, 2012): 1365–1372.
Version
Author's final manuscript
Abstract
Small-molecule ligands specific for tumor-associated surface receptors have wide applications in cancer diagnosis and therapy. Achieving high-affinity binding to the desired target is important for improving detection limits and for increasing therapeutic efficacy. However, the affinity required for maximal binding and retention remains unknown. Here, we present a systematic study of the effect of small-molecule affinity on tumor uptake in vivo with affinities spanning a range of three orders of magnitude. A pretargeted bispecific antibody with different binding affinities to different DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-based small molecules is used as a receptor proxy. In this particular system targeting carcinoembryonic antigen, a small-molecule–binding affinity of 400 pmol/L was sufficient to achieve maximal tumor targeting, and an improvement in affinity to 10 pmol/L showed no significant improvement in tumor uptake at 24 hours postinjection. We derive a simple mathematical model of tumor targeting using measurable parameters that correlates well with experimental observations. We use relations derived from the model to develop design criteria for the future development of small-molecule agents for targeted cancer therapeutics.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1158/1535-7163.mct-11-0764
